Vedolizumab treatment in a patient with X-linked agammaglobulinemia, is it safe and efficient?

Abstract excerpt

Çekiç Ş, Özgür T, Karalı Y, Özkan T, Kılıç SŞ. Vedolizumab treatment in a patient with X-linked agammaglobulinemia, is it safe and efficient? Turk J Pediatr 2019; 61: 937-940. The loss of inflammatory regulation resulting from the absence of B-lymphocytes leads to a risk for autoimmune and autoinflammatory complications. There is no data on the use of Vedolizumab in patients with X-linked agammaglobulinemia (XLA)...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Agammaglobulinaemia Tyrosine Kinase
• Share to Agammaglobulinemia